Site
Search results
U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA®) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy
Apr 04, 2017 United States GVHD is a life-threatening condition with limited treatment options Milestone highlights the potential benefit of ibrutinib beyond blood cancers RARITAN, NJ, April 4, 2017 – Janssen Research & Development, LLC announced ...
U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy
Aug 02, 2017 United States The approval provides an important new treatment option for adults living with debilitating and potentially life-threatening condition This is the first indication for IMBRUVICA outside of oncology and its sixth U.S. indication ...